Plasma extracellular vesicle transcriptome as a dynamic liquid biopsy in acute heart failure
Author:
Gokulnath PriyankaORCID, Spanos MichailORCID, Lehmann H. ImmoORCID, Sheng QuanhuORCID, Rodosthenous RodosthenisORCID, Chaffin MarkORCID, Varrias DimitriosORCID, Chatterjee EmeliORCID, Hutchins ElizabethORCID, Li GuopingORCID, Daaboul George, Rana Farhan, Wang Ashley Mingyi, Van Keuren-Jensen KendallORCID, Ellinor Patrick T.ORCID, Shah Ravi, Das SaumyaORCID
Abstract
ABSTRACTBackgroundAcute decompensation is associated with increased mortality in heart failure (HF) patients, though the underlying etiology remains unclear. Extracellular vesicles (EVs) and their cargo may mark specific cardiovascular physiologic states. We hypothesized that EV transcriptomic cargo, including long non-coding RNAs (lncRNAs) and mRNAs, is dynamic from the decompensated to recompensated HF state, reflecting molecular pathways relevant to adverse remodeling.MethodsWe examined differential RNA expression from circulating plasma extracellular RNA in acute HF patients at hospital admission and discharge alongside healthy controls. We leveraged different exRNA carrier isolation methods, publicly available tissue banks, and single nuclear deconvolution of human cardiac tissue to identify cell and compartment specificity of the topmost significantly differentially expressed targets. EV-derived transcript fragments were prioritized by fold change (−1.5 to + 1.5) and significance (<5% false discovery rate), and their expression in EVs was subsequently validated in 182 additional patients (24 control; 86 HFpEF; 72 HFrEF) by qRT-PCR. We finally examined the regulation of EV-derived lncRNA transcripts in human cardiac cellular stress models.ResultsWe identified 138 lncRNAs and 147 mRNAs (present mostly as fragments in EVs) differentially expressed between HF and control. Differentially expressed transcripts between HFrEF vs. control were primarily cardiomyocyte derived, while those between HFpEF vs. control originated from multiple organs and different (non-cardiomyocyte) cell types within the myocardium. We validated 5 lncRNAs and 6 mRNAs to differentiate between HF and control. Of those, 4 lncRNAs (AC092656.1, lnc-CALML5-7, LINC00989, RMRP) were altered by decongestion, with their levels independent of weight changes during hospitalization. Further, these 4 lncRNAs dynamically responded to stress in cardiomyocytes and pericytesin vitro, with a directionality mirroring the acute congested state.ConclusionCirculating EV transcriptome is significantly altered during acute HF, with distinct cell and organ specificity in HFpEF vs. HFrEF consistent with a multi-organ vs. cardiac origin, respectively. Plasma EV-derived lncRNA fragments were more dynamically regulated with acute HF therapy independent of weight change (relative to mRNAs). This dynamicity was further demonstrated with cellular stressin vitro. Prioritizing transcriptional changes in plasma circulating EVs with HF therapy may be a fruitful approach to HF subtype-specific mechanistic discovery.CLINICAL PERSPECTIVEWhat is new?We performed extracellular transcriptomic analysis on the plasma of patients with acute decompensated heart failure (HFrEF and HFpEF) before and after decongestive efforts.Long non-coding RNAs (lncRNAs) within extracellular vesicles (EVs) changed dynamically upon decongestion in concordance with changes within human iPSC-derived cardiomyocytes under stress.In acute decompensated HFrEF, EV RNAs are mainly derived from cardiomyocytes, whereas in HFpEF, EV RNAs appear to have broader, non-cardiomyocyte origins.What are the clinical implications?Given their concordance between human expression profiles and dynamicin vitroresponses, lncRNAs within EVs during acute HF may provide insight into potential therapeutic targets and mechanistically relevant pathways.These findings provide a “liquid biopsy” support for the burgeoning concept of HFpEF as a systemic disorder extending beyond the heart, as opposed to a more cardiac-focused physiology in HFrEF.
Publisher
Cold Spring Harbor Laboratory
Reference50 articles.
1. Fonarow GC . The Acute Decompensated Heart Failure National Registry (ADHERE™): Opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003;4. 2. Mentz RJ , O’Connor CM . Pathophysiology and clinical evaluation of acute heart failure. Nat Rev Cardiol. 2016;13. 3. Bishu K , Deswal A , Chen HH , Lewinter MM , Lewis GD , Semigran MJ , Borlaug BA , McNulty S , Hernandez AF , Braunwald E , Redfield MM . Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. Am Heart J. 2012;164. 4. Sanders-Van Wijk S , Tromp J , Beussink-Nelson L , Hage C , Svedlund S , Saraste A , Swat SA , Sanchez C , Njoroge J , Tan RS , Fermer ML , Gan LM , Lund LH , Lam CSP , Shah SJ . Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction Results From the PROMIS-HFpEF Study. Circulation. 2020;142. 5. Genetic architecture of heart failure with preserved versus reduced ejection fraction;Nat Commun [Internet],2022
|
|